ALBUQUERQUE, N.M., Aug. 10, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the appointment of Eric Tornoe as President and Chief Operating Officer.
Tornoe has more than 20 years of healthcare industry experience in sales, sales management and marketing, making him a key hire as Exagen broadens its test menu and moves to the next level of growth. Prior to Exagen, he worked for Pfizer Inc., Wyeth and Bristol-Myers Squibb Co., quickly advancing his career in a number of senior management positions that dramatically expanded revenues. He has a reputation for building effective business units, creating partnerships and developing collaborative relationships. Tornoe has a depth of operational expertise in the rheumatology market and a track record of successfully developing and implementing strategic plans.
"This is an exciting time at Exagen as our product line expands and sales grow," said Scott Glenn, board chairman and CEO. "Eric has a great track record in leading and directing teams to exceed corporate business and revenue objectives. He will play an instrumental role in the ongoing success of the company and its continued focus on personalized medicine."
Exagen is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.Using Coperna, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.
SOURCE Exagen Diagnostics, Inc.